Brought to you by 
Euthymics raises $5.2mm in first tranche of Series A round; adds money in multiple tranches
28 Jun 2012
Executive Summary
Concurrent with the closing of its $2mm acquisition of Dov Pharmaceutical, Euthymics Bioscience Inc. (developing antidepressants) has raised $5.2mm in the first tranche of a $24mm Series A financing led by Novartis Venture Funds and Venture Investors with additional participation from Hambrecht & Quist Capital Management, GBS Venture Partners, and the State of Wisconsin Investment Board. Two more tranches are expected if certain milestones are met.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Euthymics raises $5.2mm in first tranche of Series A round; adds money in multiple tranches
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice